Biotech RadarJobs updated

COMPANY

Encoded Therapeutics

HQ: South San Francisco, CA source · encoded.com ↗

Clinical Phase 2

10 open jobs · last seen Oct 23, 2026 · 4 sources

Keywords: neurology gene therapy Dravet Syndrome ETX101

Location: South San Francisco, CA · source · Oct 12, 2026

Profile checked Oct 10, 2026

10Open jobs4Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, Scientific CommunicationsSan Francisco, California, United StatesOct 20, 2026Oct 11, 2026
Associate Director, Global PublicationsUnited StatesOct 9, 2026Oct 11, 2026
Director, Clinical Development (Gene Therapy)United StatesOct 7, 2026Oct 11, 2026
Manufacturing Engineer - cGMP Gene Therapy ProductionMorrisville, United StatesOct 6, 2026Oct 11, 2026
Director, Medical AffairsUnited StatesOct 3, 2026Oct 11, 2026

See all 10 jobs

Raises and deals from press releases

Raises announced in these releases: $275M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Raise Series F · $275M source ↗
  2. Trial start Phase 1/Phase 2: A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome source ↗
  3. Trial start Phase 1/Phase 2: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome source ↗
  4. Trial start Phase 1/Phase 2: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) source ↗
  5. Trial start —: Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05419492A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromePhase 1/Phase 2RecruitingMay 14, 20242028-01 (estimated)
NCT06283212A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromePhase 1/Phase 2Active, not recruitingMay 9, 20242030-10 (estimated)
NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Phase 1/Phase 2Active, not recruitingFeb 28, 20242030-09 (estimated)
NCT04537832Natural History Study of Infants and Children With Developmental and Epileptic EncephalopathiesNot listedTerminatedJan 18, 2021Mar 31, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 10

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, Scientific CommunicationsSan Francisco, California, United StatesOct 20, 2026Oct 11, 2026Not stated
Associate Director, Global PublicationsUnited StatesOct 9, 2026Oct 11, 2026Senior
Director, Clinical Development (Gene Therapy)United StatesOct 7, 2026Oct 11, 2026Senior
Manufacturing Engineer - cGMP Gene Therapy ProductionMorrisville, United StatesOct 6, 2026Oct 11, 2026Entry
Director, Medical AffairsUnited StatesOct 3, 2026Oct 11, 2026Senior
Associate Director, Medical Writing (Clinical and Regulatory)United StatesSep 25, 2026Oct 11, 2026Senior
Manager, Regulatory Affairs (Gene Therapy)United StatesSep 23, 2026Oct 11, 2026Senior
Senior Drug Product EngineerMorrisville, North Carolina, United StatesSep 4, 2026Oct 11, 2026Senior
Engineer, Process Sciences - UpstreamMorrisville, North Carolina, United StatesAug 31, 2026Oct 11, 2026Mid
Senior Engineer, Process Sciences - Drug ProductMorrisville, North Carolina, United StatesAug 26, 2026Oct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Encoded Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback